C

Crescent Biopharma

Clinical-stage biotech developing solid-tumor therapies

Executive Director - Regulatory Affairs CMC

Regulatory & Quality (Life Sciences)Confirmed live in the last 24 hours
Full-timeWaltham, MA, USAIn-person

About the Job

Requirements

  • A Bachelor of Science or Bachelor of Arts degree in a scientific discipline and an advanced degree such as a Master of Science or Ph.D. are required.
  • At least 12 years of experience in Regulatory Affairs CMC in the pharmaceutical or biotechnology industry.
  • Strong negotiation skills with health authorities such as the FDA and EMA, as well as experience with submissions.
  • Experience leading Investigational New Drug (IND) applications and marketing applications.
  • Experience with antibody-drug conjugates and biologics.
  • Strong analytical, strategic-thinking, and problem-solving skills.
  • Excellent communication and leadership abilities, with the ability to influence across all levels of the organization.
  • Ability to thrive in a fast-paced, ambiguous environment while managing competing priorities.
  • Commitment to fostering a diverse and inclusive workplace.

Responsibilities

  • Lead and/or oversee global regulatory CMC submissions, including INDs, Clinical Trial Applications (CTAs), Biologics License Applications (BLAs), and Marketing Authorization Applications (MAAs), throughout the product lifecycle.
  • Proactively identify regulatory risks, opportunities, and mitigation strategies aligned with objectives, and communicate them to management as needed.
  • Provide strategic regulatory guidance to Technical Operations and Quality organizations to ensure global compliance and readiness for clinical and commercial supply.
  • Serve as the primary interface with global regulatory agencies for CMC-related negotiations, milestone meetings, and information requests.
  • Provide global regulatory input and support for product-compliance activities, including change controls, deviations, and investigations.
  • Manage junior team members and contractors to support development activities.

About the Company

Crescent Biopharma

Clinical-stage biotech developing solid-tumor therapies

Crescent Biopharma develops oncology therapies for solid tumors, led by CR-001, a tetravalent bispecific antibody that blocks PD-1 and VEGF to boost anti-tumor immunity while inhibiting tumor blood vessel growth. CR-001 sits in a global Phase 1/2 ASCEND trial, and the pipeline also includes CR-002, an anti-PD-L1 antibody-drug conjugate, and CR-003, an ITGB6-targeted ADC. The company differentiates itself by combining immune checkpoint blockade with VEGF inhibition and other targeted modalities to build an immuno-oncology backbone for solid tumors, supported by strategic partnerships and substantial private placements. Crescent’s goal is to advance multi-agent regimens toward regulatory approval and commercial development for patients with solid tumors.

Company size
51-200
Company stage
IPO
Headquarters
Waltham, MA
Founded
2003

Recently Posted Jobs

Explore more opportunities at Crescent Biopharma

See more jobs